Evidence map›Paper›PMID 25729661›Full record

ArticleAnesthesiology and pain medicine2011

Efficacy of botulinum toxin type a for treating chronic low back pain.

Seyed M Jazayeri, Alireza Ashraf, Habib M Fini, Hajar Karimian, Mohamadreza V Nasab

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Anesthesiology and pain medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Seyed M JazayeriDepartment of Physical Medicine and Rehabilitation, Shiraz University of Medical Sciences, Shiraz, Iran.
Alireza AshrafDepartment of Physical Medicine and Rehabilitation, Shiraz University of Medical Sciences, Shiraz, Iran.
Habib M FiniDepartment of Physical Medicine and Rehabilitation, Shiraz University of Medical Sciences, Shiraz, Iran.
Hajar KarimianDepartment of Physical Medicine and Rehabilitation, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohamadreza V NasabDepartment of Physical Medicine and Rehabilitation, Shahid Sadughi University of Medical Sciences, Yazd, Iran.
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLow back pain is a major cause of disability and can result in substantial morbidity and high healthcare costs. Botulinum toxin has been used successfully to alleviate pain for a number of conditions caused by muscle contractions or spasms.

objectivesThe aim of this study was to investigate the efficacy of botulinum toxin type A (BoNT-A; Dysport®, Ipsen, UK) for treating chronic low back pain (CLBP). PATIENTS AND

methodsThis was a single-blind, randomized clinical trial study. Fifty patients with CLBP received either BoNT-A (40 Ipsen units per injection) or saline in 5 sites in the paraspinal muscles (n = 25 per group). A visual analogue system (VAS) was used to measure pain levels at baseline and at 4 and 8 weeks post-injection. Disability was assessed using the Oswestry low back pain disability questionnaire at baseline and at 8 weeks post-injection.

resultsAfter 4 weeks, 76% of patients in the BoNT-A group reported pain relief compared to 20% in the saline group (P < 0. 005). Additionally, greater pain relief was experienced by patients in the BoNT-A group at 8 weeks (64% vs. 12%; P < 0. 001). By week 8, significant functional improvement (a minimum two-grade improvement between baseline and post-treatment assessments) was demonstrated in a higher number of patients receiving BoNT-A than in the saline group (68% vs. 12% , respectively; P < 0. 005). Patients experienced only minor side effects.

conclusionsBoNT-A improves CLBP with a low incidence of side effects and can be used as a therapeutic tool in the management of these patients.

Indexed as

Botulinum toxin type ALow back painPain

Identifiers

PMID25729661
PMCPMC4335729
OpenAlexW2126355499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.